Konvomep is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 7 US drug patents filed from 2022 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 01, 2040. Details of Konvomep's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11771686 | Compositions and kits for omeprazole suspension |
Mar, 2040
(14 years from now) | Active |
| US12329752 | Compositions and kits for omeprazole suspension |
Jul, 2039
(13 years from now) | Active |
| US11911473 | Compositions and kits for omeprazole suspension |
Jul, 2039
(13 years from now) | Active |
| US11103492 | Compositions and kits for omeprazole suspension |
Jul, 2039
(13 years from now) | Active |
| US11633478 | Compositions and kits for Omeprazole suspension |
Jul, 2039
(13 years from now) | Active |
| US12042539 | Compositions and kits for Omeprazole suspension |
Jul, 2039
(13 years from now) | Active |
| US10751333 | Compositions and kits for omeprazole suspension |
Jul, 2039
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Konvomep's patents.
Latest Legal Activities on Konvomep's Patents
Given below is the list of recent legal activities going on the following patents of Konvomep.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eGrant Notification | 27 Feb, 2024 | US11911473 |
| Email Notification
Critical | 27 Feb, 2024 | US11911473 |
| Patent Issue Date Used in PTA Calculation
Critical | 27 Feb, 2024 | US11911473 |
| Patent eGrant Notification | 27 Feb, 2024 | US11911473 |
| Recordation of Patent Grant Mailed
Critical | 27 Feb, 2024 | US11911473 |
| Recordation of Patent eGrant | 27 Feb, 2024 | US11911473 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Feb, 2024 | US10751333 |
| Email Notification
Critical | 08 Feb, 2024 | US11911473 |
| Issue Notification Mailed
Critical | 07 Feb, 2024 | US11911473 |
| Application Is Considered Ready for Issue
Critical | 23 Jan, 2024 | US11911473 |
US patents provide insights into the exclusivity only within the United States, but
Konvomep is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Konvomep's family patents as well as insights into
ongoing legal events
on those patents.
Konvomep's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Konvomep's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 01, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Konvomep Generic API suppliers:
Omeprazole; Sodium Bicarbonate is the generic name for the brand Konvomep. 11 different companies have already filed for the generic of Konvomep, with Strides Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Konvomep's generic
Alternative Brands for Konvomep
Konvomep which is used for reducing the risk of upper gastrointestinal bleeding and short-term treatment of active benign gastric ulcers in critically ill patients., has several other brand drugs in the same treatment category and using the same active ingredient (Omeprazole; Sodium Bicarbonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Salix |
| |||
| Santarus |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Omeprazole; Sodium Bicarbonate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Riley Consumer |
| |
| Santarus |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Omeprazole; Sodium Bicarbonate, Konvomep's active ingredient. Check the complete list of approved generic manufacturers for Konvomep
About Konvomep
Konvomep is a drug owned by Azurity Pharmaceuticals Inc. It is used for reducing the risk of upper gastrointestinal bleeding and short-term treatment of active benign gastric ulcers in critically ill patients. Konvomep uses Omeprazole; Sodium Bicarbonate as an active ingredient. Konvomep was launched by Azurity in 2022.
Approval Date:
Konvomep was approved by FDA for market use on 30 August, 2022.
Active Ingredient:
Konvomep uses Omeprazole; Sodium Bicarbonate as the active ingredient. Check out other Drugs and Companies using Omeprazole; Sodium Bicarbonate ingredient
Treatment:
Konvomep is used for reducing the risk of upper gastrointestinal bleeding and short-term treatment of active benign gastric ulcers in critically ill patients.
Dosage:
Konvomep is available in for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG/ML;84MG/ML | FOR SUSPENSION | Prescription | ORAL |